Zacks Investment Research cut shares of TOCAGEN INC (NASDAQ:TOCA) from a hold rating to a sell rating in a report issued on Tuesday morning.
According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “
Other analysts have also issued reports about the company. Stifel Nicolaus assumed coverage on TOCAGEN INC in a report on Monday, May 15th. They set a buy rating and a $24.00 price objective for the company. Leerink Swann assumed coverage on TOCAGEN INC in a report on Monday, May 15th. They set a mkt perform rating and a $19.00 price objective for the company. Finally, Evercore ISI reissued an outperform rating and set a $28.00 price objective on shares of TOCAGEN INC in a report on Tuesday, May 9th.
TOCAGEN INC (NASDAQ TOCA) opened at 13.02 on Tuesday. The company’s 50-day moving average price is $11.00 and its 200 day moving average price is $13.47. The firm’s market capitalization is $212.62 million. TOCAGEN INC has a 12 month low of $9.68 and a 12 month high of $17.95.
TOCAGEN INC (NASDAQ:TOCA) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.04. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. On average, equities research analysts predict that TOCAGEN INC will post ($2.81) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This article was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.baseball-news-blog.com/2017/08/19/tocagen-inc-toca-downgraded-by-zacks-investment-research-to-sell.html.
Institutional investors have recently added to or reduced their stakes in the stock. EcoR1 Capital LLC acquired a new position in TOCAGEN INC during the second quarter valued at about $18,074,000. FMR LLC acquired a new position in TOCAGEN INC during the second quarter valued at about $9,624,000. Vanguard Group Inc. acquired a new position in TOCAGEN INC during the second quarter valued at about $5,036,000. JPMorgan Chase & Co. acquired a new position in TOCAGEN INC during the second quarter valued at about $4,960,000. Finally, Nicholas Investment Partners LP acquired a new position in TOCAGEN INC during the second quarter valued at about $228,000. 0.72% of the stock is owned by institutional investors.
About TOCAGEN INC
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TOCAGEN INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TOCAGEN INC and related companies with MarketBeat.com's FREE daily email newsletter.